Updated every five years, this series provides a quick yet thorough overview of the synthetic routines that have been used to access specific classes of therapeutic agents. Materials are organized by chemical class, and syntheses are taken back to available starting materials. Disease state, rationale for method of drug therapy, biological activities of each compound and preparation are discussed, with coverage also including those generic pharmaceutical compounds t accorded clinical status. A glossary defines the biological terms.
Daniel Lednicer, PhD, is the author of several books on drug synthesis and discovery. His career in both the private and public sectors has been devoted to the search for new therapeutic agents. Dr. Lednicer spent two decades at the bench as a chemist at the Upjohn Company. Following that, he served as director of chemical research at Mead Johnson, director of pharmaceutical sciences at Adria Laboratories, and pharmaceutical manager at Analytical Biochemistry Laboratories. Most recently, he was a project officer at the National Cancer Institute.